4D Advisors LLC Invests $5 Million in Masimo Corporation $MASI

Key Points

• 4D Advisors LLC has acquired 30,000 shares of Masimo Corporation, valued at approximately $4.99 million, making it the firm's 9th largest position.
• Prominent investors, including Massachusetts Financial Services and T. Rowe Price, have also increased their holdings in Masimo, indicating strong institutional interest in the company.
• Masimo recently reported an EPS of $1.33, exceeding analyst estimates, with year-over-year revenue growth of 7.7% during its latest earnings call.

4D Advisors LLC purchased a new stake in Masimo Corporation (NASDAQ:MASI - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 30,000 shares of the medical equipment provider's stock, valued at approximately $4,998,000. Masimo makes up approximately 3.9% of 4D Advisors LLC's investment portfolio, making the stock its 9th biggest holding. 4D Advisors LLC owned approximately 0.06% of Masimo at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA grew its stake in Masimo by 13.4% in the first quarter. Massachusetts Financial Services Co. MA now owns 1,967,838 shares of the medical equipment provider's stock valued at $327,842,000 after purchasing an additional 232,671 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in shares of Masimo by 0.7% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,673,252 shares of the medical equipment provider's stock worth $278,764,000 after acquiring an additional 10,876 shares during the period. Durable Capital Partners LP bought a new position in shares of Masimo during the 1st quarter worth approximately $187,528,000. Dimensional Fund Advisors LP boosted its stake in shares of Masimo by 8.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 703,378 shares of the medical equipment provider's stock worth $117,172,000 after acquiring an additional 55,658 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of Masimo by 27.5% during the 4th quarter. Northern Trust Corp now owns 383,869 shares of the medical equipment provider's stock worth $63,454,000 after acquiring an additional 82,828 shares during the period. 85.96% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. BTIG Research reiterated a "buy" rating on shares of Masimo in a research note on Thursday, August 14th. Wall Street Zen downgraded Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Zacks Research upgraded Masimo from a "hold" rating to a "strong-buy" rating in a research note on Wednesday. Finally, Piper Sandler lifted their target price on Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $193.60.

Masimo Price Performance

NASDAQ MASI traded up $4.18 during midday trading on Friday, hitting $147.19. The company had a trading volume of 693,981 shares, compared to its average volume of 649,554. The company has a market capitalization of $8.00 billion, a PE ratio of -17.28 and a beta of 1.23. The company has a current ratio of 2.14, a quick ratio of 1.61 and a debt-to-equity ratio of 0.57. The firm has a 50-day moving average price of $154.41 and a 200-day moving average price of $160.39. Masimo Corporation has a twelve month low of $107.98 and a twelve month high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.11. The firm had revenue of $370.90 million during the quarter, compared to analysts' expectations of $368.65 million. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.The company's quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.86 EPS. As a group, analysts anticipate that Masimo Corporation will post 4.1 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director William R. Jellison acquired 3,000 shares of the company's stock in a transaction on Monday, August 11th. The stock was purchased at an average cost of $145.98 per share, with a total value of $437,940.00. Following the acquisition, the director directly owned 4,790 shares of the company's stock, valued at approximately $699,244.20. The trade was a 167.60% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.70% of the stock is owned by corporate insiders.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.